CN1156026A - Application of N-aceto-D-aminoglucose in medicinal preparation for curing respiratory tract diseases - Google Patents
Application of N-aceto-D-aminoglucose in medicinal preparation for curing respiratory tract diseases Download PDFInfo
- Publication number
- CN1156026A CN1156026A CN 96117865 CN96117865A CN1156026A CN 1156026 A CN1156026 A CN 1156026A CN 96117865 CN96117865 CN 96117865 CN 96117865 A CN96117865 A CN 96117865A CN 1156026 A CN1156026 A CN 1156026A
- Authority
- CN
- China
- Prior art keywords
- acetyl
- respiratory tract
- application
- formula
- chemical compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A known compound N-acetyl-D-glucosamine as active component is mixed with more pharmacologically acceptable excipient and/or carrier to prepare medicine in liquid or solid state through mixing, granulating, tabletting and coating, which is used to cure diseases in respiratory tract with distinct curative effect and no any by-effect.
Description
The present invention relates to the application of N-acetyl-D-amino glucose as medicine, the particularly N-acetyl-D-amino glucose application in the pharmaceutical preparation of treatment respiratory tract disease.
N-acetyl-D-amino glucose is as a chemical reagent, public offering on market.Zui Da reagent company-Sigma company obtains this product with chemical synthesis with the glucosamine acetylation in the world, is to use as a kind of biochemical analysis reagent always.
External research work about N-acetyl-D-amino glucose therapeutical effect starts from Crevenlien in 1991 and is used for mouse test with it, find that N-acetyl-D-amino glucose can make cartilage glycosaminoglycans increase, thereby alleviate the pathological change of cartilage; Garcelon in 1987 etc. will contain N-acetyl-D-amino glucose preparation RHINAAXIA and try out in clinical, and 186 Allergic Rhinitis are treated, and obtain curative effect preferably.
Biochemical studies show that can produce N-acetyl-D-amino Portugal glucose under the human body normal condition.As a chemical compound, it can be in human body normal presence.Since atomic at normal human's intensive amount, more deep research is not carried out in its metabolism, and biochemical research also never relates to the influence of this material to human body physiological function.In recent years; the Japan scientist recognizes the effect of hyaluronic acid in human body gradually in the researching human body scientific process; hyaluronic acid is a kind of viscoelastic material; the macromolecular compound that the N-acetyl-D-amino glucose of medium molecule and D-glucuronic acid are formed; hyaluronic acid and water form viscous gel, and effect lubricated and the protection cell is arranged.And contain hyaluronidase in some antibacterial, malignant tumor and the snake venom; hyaluronic acid is decomposed; viscosity reduces; pathogen is invaded and is propagated; therefore say that hyaluronic acid is the important substance of protection body health, and have great importance too as the N-acetyl-D-amino glucose of one of synthetic hyaluronic raw material.
We have set up antibacterial fluctuation growth model when carrying out " biological ripple " Study on Theory, to this fluctuation its intrinsic regulatory mechanism is arranged through study and cognition, mainly finish by some chemical substance.These chemical substances with regulating action can promote biological fluctuation, and the order slow wave of morbid state is transformed into the fast wave that is chaos state normally, and we call the short ripple factor to this material.Its separation and Extraction is come out and identify, be confirmed as N-acetyl-D-amino glucose at last, what its short ripple effect may be with its pair cell is lubricated relevant with protective effect, because of its short ripple effect, is called as and urgees the ripple amino sugar.Many functions of human body need be urged the ripple factor and assist to finish, and then can cause unusual condition when this short ripple factor lacks in the body.
After the upper respiratory tract infection and the concurrent bacterial infection of catching a cold are the due to illness former infection of tissue adherence cell, produce damage, cause the bacterial infection of secondary.Therefore, treatment must consider that promptly tissue adherence resumes treatment and antibacterial therapy from two aspects.And existing conventional is treated the antibiotic directed toward bacteria effect of adopting, and can not improve the damaged tissues situation, and because clusters of bacteria tolerates phenomenon to antibiotic ecology, so that the concurrent bacterial infection in flu back almost is inevitable.
The objective of the invention is to: the new pharmaceutical usage that utilizes N-acetyl-D-amino glucose to be had, make treatment upper respiratory tract infection and flu back bacterial infection medicine, to overcome the deficiency that the existing conventional medicine in use exists.
Above-mentioned purpose of the present invention is achieved in that promptly adopting structural formula is that the chemical compound of (1) is made active component; with multiple pharmaceutically acceptable excipient or/and carrier combine; adopt mixing, granulation, in flakes, known methods such as sweet tablet or film bag table are prepared into liquid state or solid formulation form, are used for the treatment of upper respiratory tract infection and flu back bacterial infective diseases.
Wherein, the chemical name of structural formula (I) is N-acetyl-D-glucamine (N-Acetyl-D-glucosamine), molecular formula: C
6H
15NO
6, structure is expressed as follows:
The pharmaceutical usage that the present invention provides formula (I) chemical compound is because after the upper respiratory tract infection and the concurrent bacterial infection of catching a cold be the due to illness former infection of tissue adherence cell, produce damage, causes the bacterial infection of secondary.According to relevant biological ripple Study on Theory, discoverable type (I) chemical compound has the function that promotes the biological cell fluctuation, and this function may show as effect lubricated and the protection cell, with infringement and the propagation of pathogen in cell of avoiding the pathogen pair cell.Result of the test through antibacterium field planting effect shows, formula (I) is not though chemical compound has the bactericidal effect, but the antibacterial to the respiratory mucosa surface has anti-field planting effect, it can cooperate the ciliary movement on respiratory tract surface to get rid of antibacterial external, simultaneously by promoting that cell distributes again, improve and repair local damaged tissues, thereby play the purpose of anti-inflammatory.
The toxicological test of formula (I) chemical compound comprises:
1. acute toxicity test: comprise oral, intravenous injection and maximum limit amount medicine-feeding test;
2.Ames test;
3. mouse marrow cell micro nuclear test;
4. the abnormal property of Mus sperm test;
5. mouse testis chromosomal aberration test;
6. show the chronic lethal test;
7. subchronic toxicity (feeding in 90 days) test;
8. traditional teratogenicity test.
Conclusion (of pressure testing) shows: formula (I) chemical compound acute toxicity test dosage surpasses 2g/kg, is 300 times of people's injected dose, does not occur the acute poisoning reaction yet; In long term toxicity test, maximum dose level has reached lg/kg, and toxic reaction does not appear in experimental observation around the warp; In reproduction test, feed mice from routine dose 7mg/kg, go down to posterity through three times, prove formula (I) chemical compound to mice become pregnant, gestation, childbirth, suckling and filial mice growth all do not have influence.Proof formula (I) chemical compound belongs to innocuous substance.
Formula (I) chemical compound shows that in clinical a large amount of situations on probation this medicine can effectively prevent or treat the upper respiratory tract active chronic inflammation.Acute upper respiratory tract infection comprises acute pharyngitis, acute laryngitis, acute sinusitis, shows through 300 routine clinical employing buccal tablet result on trial, and formula (I) chemical compound reaches more than 90% the effective percentage of treatment acute upper respiratory tract infection; It should be noted that to the emergency case patient, escalated dose is answered in first and second day administration.Chronic upper respiratory tract infection comprises chronic pharyngitis, chronic laryngitis, chronic rhinitis, shows through 150 routine clinical oral administration administration result on trial, and formula (I) chemical compound is 62% to the cure rate of treatment chronic upper respiratory tract infection.
Formula (I) chemical compound can pass through common administration, and parenterai administration for example is as intravenous injection or oral administration.Dosage depends on patient's age, body weight, condition of illness and route of administration.Make suitable dosage and be adult's dosage 150-300mg/ day, intravenous injection once, oral or intramuscular injection divides three times; Seven days is a course of treatment, the hard special 2-3 administration course of treatment.
Can adopt conventional method to prepare the pharmaceutically pharmaceutical composition of suitable formulations form.For example, the preparation that is used for liquid form used for intravenous injection or for oral use can be a solvent with sterilized water or Sterile Saline.The suspension of intramuscular injection or solution can adopt in the carrier Peroral solid dosage form forms such as sterilized water, olive oil, ethyl oleate, glycols, for example tablet or chamber capsule, remove formula (I) active ingredient beyond the region of objective existence, also can comprise diluent, as lactose, glucose, cellulose, starch; Lubricant is as silicon, Talcum, magnesium stearate or calcium and Polyethylene Glycol; Bonding agent is as starch, Radix Acaciae senegalis, methylcellulose, carboxymethyl cellulose, polyvinylpyrrolidone; Depolymerizing agent is as starch, alginic acid, alginate, sodium starch glycol; Foaming mixture; Coloring agent; Sweeting agent; Lubricant is as lecithin, many ethoxies fat ether etc.; General nontoxic and pharmacology goes up inert matter and can be used in the pharmaceutical preparation.Said pharmaceutical preparation can prepare with known method, for example utilize mixing, granulation, in flakes, methods such as sugar-coating or film-coating
Formula disclosed by the invention (I) chemical compound is different from the new medical usage of its known application, enlarged the range of application of N-acetyl-D-amino glucose, having improved its exploitation is worth, with it is that active substance is except that being used to prepare the medicine for the treatment of respiratory tract disease, also can be used as additive and be used for health product, help the prevention of respiratory tract disease.Have special effect and remarkable, compound method is simple, and advantage without any side effects from promoting that cell distributes again, is adjusted the angle of biological ripple, has innovative characteristics.
Claims (1)
1.N-the application of acetyl-D-amino glucose in the pharmaceutical preparation of treatment respiratory tract disease, it is characterized in that: adopt structural formula to make active component for the chemical compound of (I), with multiple pharmaceutically acceptable excipient or/and carrier combine, adopt mixing, granulation, in flakes, known methods such as steamed bun stuffed with sugar table or film bag table are prepared into the preparation of liquid state or solid-state form;
Wherein, the chemical name of structural formula (1) is N-acetyl-D-glucamine (N-Acetyl-D-glucosamine), molecular formula: C
8H
15NO
6, structure is expressed as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96117865A CN1067245C (en) | 1996-12-27 | 1996-12-27 | Application of N-aceto-D-aminoglucose in medicinal preparation for curing respiratory tract diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96117865A CN1067245C (en) | 1996-12-27 | 1996-12-27 | Application of N-aceto-D-aminoglucose in medicinal preparation for curing respiratory tract diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1156026A true CN1156026A (en) | 1997-08-06 |
| CN1067245C CN1067245C (en) | 2001-06-20 |
Family
ID=5124681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96117865A Expired - Fee Related CN1067245C (en) | 1996-12-27 | 1996-12-27 | Application of N-aceto-D-aminoglucose in medicinal preparation for curing respiratory tract diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1067245C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002067947A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for adjuvant treatment of perianal disease |
| WO2002067949A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cardio-cerebrovascular anoxemia |
| WO2002067945A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cervical erosion |
| WO2002067944A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating motion sickness |
| WO2002067946A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy |
| WO2002067948A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for preventing and treating sexual disorder |
| JP2012531445A (en) * | 2009-07-03 | 2012-12-10 | オーストラリアン・バイオメディカル・カンパニー・プロプライアタリー・リミテッド | Medicinal carbohydrates for the treatment of respiratory conditions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3927723A1 (en) * | 1989-01-26 | 1990-08-02 | Ulrich Prof Dr Speck | N - ACETYL GLUCOSAMINE FOR BUCCAL USE |
| US5229374A (en) * | 1992-01-28 | 1993-07-20 | Burton Albert F | Method for treatment of lower gastrointestinal tract disorders |
| AU3881493A (en) * | 1992-03-19 | 1993-10-21 | University Of British Columbia, The | Method and composition for suppression of side effects of anti-inflammatory drugs |
-
1996
- 1996-12-27 CN CN96117865A patent/CN1067245C/en not_active Expired - Fee Related
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002067947A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for adjuvant treatment of perianal disease |
| WO2002067949A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cardio-cerebrovascular anoxemia |
| WO2002067945A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating cervical erosion |
| WO2002067944A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for treating motion sickness |
| WO2002067946A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy |
| WO2002067948A1 (en) * | 2001-02-28 | 2002-09-06 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for preventing and treating sexual disorder |
| US6946452B2 (en) | 2001-02-28 | 2005-09-20 | Third Military Medical University Chinese People's Liberation Army P.R. Of China | Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for treating motion sickness |
| US6992073B2 (en) | 2001-02-28 | 2006-01-31 | Third Military Medical University, Chinese People's Liberation Army | Use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating cervical erosion |
| US7015207B2 (en) | 2001-02-28 | 2006-03-21 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for preventing and treating sexual disorder |
| US7037904B2 (en) | 2001-02-28 | 2006-05-02 | Third Military Medical University, Chinese People's Liberation Army, P.R. Of China | Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for suppressing side-effect of radiotherapy and chemotherapy |
| US7074774B2 (en) | 2001-02-28 | 2006-07-11 | Third Military Medical University Chinese People's Liberation Army | Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for treating cardio-cerebrovascular anoxemia |
| JP2012531445A (en) * | 2009-07-03 | 2012-12-10 | オーストラリアン・バイオメディカル・カンパニー・プロプライアタリー・リミテッド | Medicinal carbohydrates for the treatment of respiratory conditions |
| EP2448590A4 (en) * | 2009-07-03 | 2013-05-15 | Australian Biomedical Company Pty Ltd | Medicinal carbohydrates for treatment of respiratory conditions |
| US9040503B2 (en) | 2009-07-03 | 2015-05-26 | Australian Biomedical Company Pty Ltd. | Medicinal carbohydrates for treatment of respiratory conditions |
| JP2016026170A (en) * | 2009-07-03 | 2016-02-12 | オーストラリアン・バイオメディカル・カンパニー・プロプライアタリー・リミテッド | Medicinal carbohydrates for treatment of respiratory conditions |
| US10195226B2 (en) | 2009-07-03 | 2019-02-05 | Australian Biomedical Company Pty Ltd. | Medicinal carbohydrates for treatment of respiratory conditions |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1067245C (en) | 2001-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0382840B1 (en) | Aloe compositions and uses thereof | |
| EP1429789B1 (en) | Anti-infectious carbohydrates | |
| EP1455802B1 (en) | Uses of chitosan oligosaccharides | |
| SK459890A3 (en) | USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT | |
| JP2013529598A (en) | Use of partially and fully sulfated hyaluronan | |
| US6451850B1 (en) | Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum | |
| EP2094277A1 (en) | A composition for treatment of atopic dermatitis comprising glucosamine and derivatives thereof and a method for treatment of atopic dermatitis using them | |
| CN1156027A (en) | Application of N-aceto-D-aminoglucose in medicinal preparation for curing intestinal diseases | |
| AU2007280625A1 (en) | Use of escin | |
| CN1067245C (en) | Application of N-aceto-D-aminoglucose in medicinal preparation for curing respiratory tract diseases | |
| JP2011526255A (en) | Natural allicin tablet and preparation method thereof | |
| CN1173706C (en) | Application of N-acetyl-D-aminoglucose in preparing medicines to treat cervical erosion | |
| CN1067246C (en) | Application of N-aceto-D-aminoglucose for preparing skin sanitary article preparation | |
| JP2798287B2 (en) | Anti-inflammatory agent | |
| CA2385493A1 (en) | Sebum production inhibitors | |
| KR20080009695A (en) | Healthfood and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage | |
| NZ190925A (en) | 3beta-hydroxy-5-ene(or 3beta-hydroxy-5alpha))-spiroketal steroid-3-mono-and-3-disaccharides in antiinflammatory compositions | |
| CN1131036C (en) | Application of N-acetyl-D-aminoglucose in preparing medicines to suppress by-effect of radiotherapy and chemicotherapy | |
| CN1389475A (en) | Wolfberry polysaccharide and its prepn. and application | |
| KR102227398B1 (en) | Novel Composition comprising a therapeutic material for treating arthritis of ergostenol glycoside derivatives | |
| US20050070500A1 (en) | Method of modulating release of saccharides and uses thereof | |
| JP2021529195A (en) | Use of mannuronedioic acid composition in the treatment of inflammation | |
| CN1372930A (en) | Application of N-acetyl-D-aminoglucose in preparing medicines to prevent and treat sexual disfunction | |
| KR19990026532A (en) | Prevention and improvement agent of liver function disorder caused by chitooligosaccharide | |
| EP4112060A1 (en) | Low-molecular-weight he800 exopolysaccharide derivatives with anti-cancer properties and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: MILITARY MEDICAL UNIV NO.3, P.L.A.; SUZHOU CITY B Free format text: FORMER OWNER: MILITARY MEDICAL UNIV NO.3, P.L.A. Effective date: 20051014 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20051014 Address after: Zheng Jie gaotanyan Shapingba District of Chongqing City, Sichuan Province, No. 30 400038 Co-patentee after: Suzhou Bawei Medicine Development Research Institute Co., Ltd. Patentee after: Third Military Medical University, Chinese People's Liberation Army Address before: 630038 Sichuan city of Chongqing province Shapingba gaotanyan Patentee before: Third Military Medical University, Chinese People's Liberation Army |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20010620 Termination date: 20101227 |